20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Favipiravir's Battle Against Viruses: From Influenza to Emerging Threats

Favipiravir, a compound identified by CAS number 259793-96-9, has garnered significant attention for its robust antiviral properties. Its primary mechanism of action involves the inhibition of viral RNA-dependent RNA polymerase, a critical enzyme for the replication of many RNA viruses. This core function allows Favipiravir to disrupt the viral life cycle, making it a valuable therapeutic agent.

Initially recognized for its efficacy against influenza in Japan, Favipiravir's potential extends far beyond this initial application. Its broad-spectrum antiviral activity has led to its investigation and use against a variety of other viral pathogens, including but not limited to, Ebola virus and Nipah virus. The global response to the COVID-19 pandemic has also seen extensive research into Favipiravir, with numerous favipiravir clinical trials covid-19 being conducted to assess its effectiveness against SARS-CoV-2.

The pharmaceutical industry's ability to produce Favipiravir relies on well-established favipiravir synthesis pathways. These methods ensure the production of high-purity active pharmaceutical ingredients necessary for therapeutic use. Concurrently, a thorough understanding of favipiravir side effects is paramount for its safe administration. While studies indicate a generally acceptable safety profile for short-term treatment, potential adverse reactions, such as hyperuricemia and concerns regarding teratogenicity, necessitate cautious use and patient screening.

The ongoing exploration of favipiravir antiviral activity is crucial for identifying its full therapeutic potential. From its established role in influenza treatment to its ongoing evaluation against emerging and re-emerging viral threats, Favipiravir remains a molecule of considerable interest. Its contribution to combating viral diseases, both current and future, is a subject of continuous scientific research and development.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: The Science Behind Favipiravir: Mechanism, Synthesis, and Applications

Next: The Pharmaceutical Profile of Favipiravir (CAS 259793-96-9): Efficacy, Safety, and Research

All Rights Reserved